OKYO
Income statement / Annual
Last year (2024), OKYO Pharma Limited's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, OKYO Pharma Limited's net income was -$16,825.46.
See OKYO Pharma Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$7,506.16
|
$3,797.00
|
$2,423.01
|
$13,086.00
|
$5,971.08
|
$219.17
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$7,506.16
|
-$3,797.00
|
-$2,423.01
|
-$13,086.00
|
-$5,971.08
|
-$219.17
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$8,243.57
|
$6.34 M
|
$1.61 M
|
$348,347.00
|
$517,457.00
|
$3.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$573,427.00
|
$363,199.00
|
$1.05 M
|
$1.74 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$6.75 M
|
$4.93 M
|
$2.97 M
|
$995,422.00
|
$1.85 M
|
$573,427.00
|
$363,199.00
|
$1.05 M
|
$1.74 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$15,811.92
|
-$12,427.12
|
$116,919.00
|
$48,569.00
|
$0.00
|
| Operating Expenses |
$8,243.57
|
$13.19 M
|
$6.22 M
|
$3.37 M
|
$1.51 M
|
$4.54 M
|
$1.04 M
|
$363,269.00
|
$1.10 M
|
$1.75 M
|
| Cost And Expenses |
$15,749.00
|
$13.19 M
|
$6.22 M
|
$3.37 M
|
$1.52 M
|
$4.54 M
|
$1.04 M
|
$363,269.00
|
$1.10 M
|
$1.75 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$48,065.00
|
$0.00
|
$0.00
|
$4,421.82
|
$12,358.00
|
$17,292.00
|
| Interest Expense |
$0.00
|
$96,687.00
|
$0.00
|
$1,123.00
|
$1,156.88
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3,866.00
|
$3,797.00
|
$2,331.00
|
$13,111.00
|
$5,971.08
|
$217.82
|
$104.61 M
|
$52,516.00
|
-$18,715.00
|
$0.00
|
| EBITDA |
-$15,745.87 |
-$13.18 M |
-$6.22 M |
-$3.35 M |
-$1.51 M |
-$4.54 M |
$26.17 M |
-$363,269.20 |
-$1.12 M |
-$1.75 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1,053.31
|
-$96,687.00
|
$0.00
|
$754,848.00
|
-$99,494.00
|
-$363,045.52
|
-$12,427.12
|
$121,341.00
|
$96,003.00
|
$0.00
|
| Income Before Tax |
-$16,803.05
|
-$13.28 M
|
-$6.22 M
|
-$3.38 M
|
-$1.62 M
|
-$4.90 M
|
-$28.27 M
|
-$241,927.43
|
-$1.01 M
|
-$1.49 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$22.42
|
-$12,202.00
|
-$786,521.00
|
-$24,994.00
|
-$76,194.00
|
-$171,642.18
|
$0.83
|
-$56,937.82
|
-$189,987.78
|
$6.76 M
|
| Net Income |
-$16,825.46
|
-$13.27 M
|
-$5.43 M
|
-$3.35 M
|
-$1.54 M
|
-$4.90 M
|
-$28.27 M
|
-$241,927.43
|
-$820,171.01
|
-$8.26 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.0006 |
-0.6 |
-0.36 |
-0.32 |
-0.17 |
-0.62 |
-4.8 |
-0.0413 |
-0.17 |
-1.32 |
| EPS Diluted |
-0.0006 |
-0.6 |
-0.36 |
-0.32 |
-0.17 |
-0.62 |
-4.8 |
-0.0413 |
-0.14 |
-1.42 |
| Weighted Average Shares Out |
$29.34 M
|
$22.26 M
|
$15.06 M
|
$10.35 M
|
$9.16 M
|
$7.91 M
|
$5.89 M
|
$5.86 M
|
$4.76 M
|
$6.26 M
|
| Weighted Average Shares Out Diluted |
$29.34 M
|
$22.26 M
|
$15.06 M
|
$10.35 M
|
$9.16 M
|
$7.91 M
|
$5.89 M
|
$5.86 M
|
$5.86 M
|
$5.80 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
